Tretinoin topical - Phosphagenics

Drug Profile

Tretinoin topical - Phosphagenics

Alternative Names: Retinoic acid topical; TPM-02/retinoic acid; TPM®/tretinoin; Tretinoin/TPM®

Latest Information Update: 30 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Phosphagenics
  • Class Antiacnes; Antineoplastics; Keratolytics; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Acne vulgaris

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 30 May 2016 Tretinoin topical - Phosphagenics is available for licensing in World as of 30 May 2016. http://www.phosphagenics.com
  • 08 Oct 2014 Phosphagenics completes a phase II trial in Acne vulgaris in Australia and New Zealand (Topical) (ACTRN12613000756729)
  • 07 Oct 2014 Efficacy and adverse event data from a phase II trial in Acne vulgaris released by Phosphagenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top